Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Human levator veli palatini muscle: a novel source of mesenchymal stromal cells for use in the rehabilitation of patients with congenital craniofacial malformations

Fig. 3

Immunophenotype analysis of LVPMDSCs. Related graphs, where it is possible to compare, for each of the 8 analyzed markers, the experimental population of LVPMDSCs selected in R1; for viability, we used 7-AAD staining (in red), where R2 = live cells (90%) and R3 = dead cells (10%). The experimental population of LVPMDSCs labeled with specific antibodies (in purple); we observe the following: negative reaction (< 2%) for endothelial marker CD31, 0.96%, and hematopoietic markers CD45, 1.14%, and CD34, 0.37%. Positive reaction was observed for the adhesion markers CD29, 99.82% (C); CD 90, 98.06%; and CD44, 90%, and for the mesenchymal markers CD73, 99.66%, and CD105, 97.78%. CD, cluster of differentiation

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512